Real-world comparison of neoadjuvant pembrolizumab plus chemotherapy versus tislelizumab plus chemotherapy in patients with resectable non-small cell lung cancer: a retrospective cohort study of treatment outcomes.

ABSTRACT:

Background

Pembrolizumab and tislelizumab have shown substantial clinical benefits in perioperative treatment of resectable non-small cell lung cancer (NSCLC), yet no direct head-to-head trial has established which is optimal. This study, for the first time, aimed to directly compare the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy versus tislelizumab plus chemotherapy in resectable NSCLC using real-world data.

Methods

Data of patients with resectable NSCLC treated with neoadjuvant pembrolizumab plus chemotherapy or tislelizumab plus chemotherapy followed by radical resection between December 2017 and August 2023 at the Second Xiangya Hospital of Central South University were retrospectively analyzed. Patients aged 18 years and above, diagnosed with bio

SUBMITTER: Hu Y 

PROVIDER: S-EPMC11921188 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature